DATA THROUGH MARCH 28 NUMBER OF DEATHS*: 786
NUMBER OF REPORTS: 160,071
TOTAL ADVERSE REACTIONS ACROSS ALL REPORTS: 565,660
Disorder/Report Classification | Pfizer | AstraZeneca |
Blood | 3,698 | 3,030 |
- Thrombocytopenia | 53 | 149 |
Cardiac | 1,567 | 4,325 |
- Cardiac arrest & failure | 77 | 119 |
- Percarditis or myocarditis | 24 | 30 |
Ear | 1,235 | 3,261 |
Endocrine | 25 | 80 |
Eye | 1,897 | 5,521 |
- Blindness | 19 | 73 |
- Blurred vision | 297 | 836 |
Gastrointestinal | 13,387 | 46,391 |
General & Injection Site | 36,796 | 151,940 |
Hepatic | 31 | 109 |
Immune System | 689 | 1,314 |
- Anaphylactic/anaphylactoid reactions | 259 | 457 |
Infections | 2,864 | 8,705 |
- Herpes zoster (shingles outbreak) | 357 | 349 |
- Influenza or influenza like infection | 1,588 | 10,506 |
Investigations | 1,440 | 5,251 |
Metabolic | 777 | 5,353 |
- Diabetes | 36 | 49 |
Muscle & Tissue | 16,718 | 54,835 |
Neoplasms | 53 | 82 |
Nervous System | 23,534 | 95,234 |
- Guillan-Barre | 15 | 73 |
- Stroke | 24 | 61 |
- Brain Hemorrhage | 23 | 91 |
- Coma | 2 | 9 |
- Paralysis | 33 | 134 |
- Facial paralysis (Bell's Palsy) | 269 | 219 |
- Seizures/Epilepsy | 271 | 771 |
Miscarriages | 40 | 15 |
Psychiatric | 1,942 | 8,047 |
Renal & Urinary | 311 | 1,248 |
Reproductive & Breast | 672 | 1,136 |
Respiratory | 5,200 | 12,660 |
Skin | 8,974 | 24,605 |
Vascular | 1,601 | 4,400 |
- Thrombosis (blood clot) or Embolism | 127 | 524 |
TOTAL FIRST DOSES GIVEN (millions) | 10.9 | 19.5 |
* Note: The UK only counts deaths within 1 week of vaccination. Sources here, here and here.
The UK Medicines and Healthcare Products Regulatory Agency Warning on Blood Clots
The MHRA has undertaken a thorough review into UK reports of an extremely rare and unlikely to occur specific type of blood clot in the brain, known as cerebral venous sinus thrombosis (CVST) occurring together with low levels of platelets (thrombocytopenia) following vaccination with the COVID-19 Vaccine AstraZeneca. It is also considering other blood clotting cases (thromboembolic events) alongside low platelet levels.
These reports have been analysed by the Government’s independent advisory body, the Commission on Human Medicines (CHM) and its COVID- 19 Vaccines Benefit Risk Expert Working Group, which includes lay representatives and advice from leading haematologists.
Up to and including 31 March 2021, the MHRA had received 79 UK reports of blood clotting cases alongside low levels of platelets following the use of the COVID-19 Vaccine AstraZeneca:
As a precaution, administration of COVID-19 Vaccine AstraZeneca in people of any age who are at higher risk of blood clots because of their medical condition should be considered only if benefits from the protection from COVID-19 infection outweighs potential risks.
Anyone who experienced cerebral or other major blood clots occurring with low levels of platelets after their first vaccine dose of COVID-19 Vaccine AstraZeneca should not have their second dose. Anyone who did not have these side effects should come forward for their second dose when invited.
The MHRA recently confirmed that the evidence to date does not suggest that the COVID-19 Vaccine AstraZeneca causes venous thromboembolism without a low platelet count.
To note, the current analysis prints include data up to, and including, the 28 March; the data provided in this summary of thrombo-embolic events reflect data assessed up to 31st March after a thorough review. Direct comparison of the summary provided here and the analysis prints is not possible since this summary has been subject to thorough review which considers each report as a whole, rather than on an individual reaction basis.
Thanks, ransomnote!